Physician profile
Amit Om
NPI 1336599232
$7,333.49
in general payments reported to CMS, 2019-2025
33 companies · $1,613 in 2025
The $1,613 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,173 · 2020: $1,066 · 2021: $19.88 · 2022: $368 · 2023: $280 · 2024: $813 · 2025: $1,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.07 |
| Education | $192.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,060.79 | 2019-2025 | |
| Lilly USA, LLC | $488.55 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $398.86 | 2019-2025 | |
| Janssen Biotech, INC. | $371.07 | 2024-2025 | Tremfya |
| Pfizer INC. | $366.12 | 2019-2025 | |
| Genzyme Corporation | $325.79 | 2023-2025 | |
| Galderma Laboratories, L.P. | $309.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $293.62 | 2019-2025 | Dupixent |
| Ucb, INC. | $263.67 | 2020-2025 | Bimzelx |
| Amgen INC. | $230.55 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $227.64 | 2019-2025 | |
| Allergan, INC. | $215.59 | 2019 | |
| Celgene Corporation | $213.66 | 2019 | |
| Kerecis Limited | $191.96 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Organon LLC | $168.44 | 2025 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $167.21 | 2024-2025 | Opzelura, Opzelura |
| Almirall LLC | $134.91 | 2019 | |
| Merz North America, INC. | $124.74 | 2022 | |
| Stemline Therapeutics INC. | $122.40 | 2020 | |
| Arcutis Biotherapeutics, INC. | $118.97 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $99.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $88.72 | 2022-2024 | Sotyktu |
| Dermira, INC. | $78.68 | 2019 | |
| Convatec INC. | $76.32 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $35.63 | 2022 | |
| Revance Therapeutics, INC. | $28.18 | 2024 | Daxxify |
| Leo Pharma INC. | $26.12 | 2022 | |
| Hill Dermaceuticals, INC. | $21.53 | 2025 | Tolak |
| Misonix INC | $19.88 | 2021 | |
| Botanix Sb INC | $17.86 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.70 | 2024 | Spevigo |
| Tempus Ai, INC | $15.93 | 2024 | |
| Dermavant Sciences, INC. | $14.00 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Om listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.